These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 8180297)

  • 41. Is it time to adopt proton pump inhibitors in the prevention of non-steroidal anti-inflammatory drug gastropathy?
    Malki SA; Yeomans ND
    Dig Liver Dis; 2000 Apr; 32(3):209-10. PubMed ID: 10975770
    [No Abstract]   [Full Text] [Related]  

  • 42. Lack of pantoprazole drug interactions in man.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Omeprazole: long-term safety.
    Arnold R; Koop H
    Digestion; 1989; 44 Suppl 1():77-86. PubMed ID: 2691313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
    Diav-Citrin O; Arnon J; Shechtman S; Schaefer C; van Tonningen MR; Clementi M; De Santis M; Robert-Gnansia E; Valti E; Malm H; Ornoy A
    Aliment Pharmacol Ther; 2005 Feb; 21(3):269-75. PubMed ID: 15691301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity.
    Parsons ME
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S15-20. PubMed ID: 8930575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
    Pan WJ; Goldwater DR; Zhang Y; Pilmer BL; Hunt RH
    Aliment Pharmacol Ther; 2000 Mar; 14(3):345-52. PubMed ID: 10735929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pantoprazole versus omeprazole in the treatment of reflux esophagitis.
    Vcev A; Stimac D; Vceva A; Takac B; Ivandić A; Pezerović D; Horvat D; Nedić P; Kotromanović Z; Maksimović Z; Vranjes Z; Males J; Jurisić-Orzen D; Vladika I; Stimac T; Mandić B
    Acta Med Croatica; 1999; 53(2):79-82. PubMed ID: 10705625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pantoprazole and cyclosporine or tacrolimus.
    Schwrer H; Lorf T; Ringe B; Ramadori G
    Aliment Pharmacol Ther; 2001 Apr; 15(4):561-2. PubMed ID: 11284790
    [No Abstract]   [Full Text] [Related]  

  • 50. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.
    Witzel L; Gütz H; Hüttemann W; Schepp W
    Aliment Pharmacol Ther; 1995 Feb; 9(1):19-24. PubMed ID: 7766739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors.
    Masubuchi N; Okazaki O
    Chem Biol Interact; 1997 Nov; 107(1-2):63-74. PubMed ID: 9402950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence].
    Bustamante Baléna M; Ponce García J
    Rev Clin Esp; 2004 Mar; 204(3):161-8. PubMed ID: 15025985
    [No Abstract]   [Full Text] [Related]  

  • 53. Lack of pantoprazole drug interactions in man: an updated review.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1996 Jun; 34(6):243-62. PubMed ID: 8793611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Drug interactions. Proton pump inhibitors. 1].
    Gleiter CH
    Internist (Berl); 1998 Aug; 39(8):874-5. PubMed ID: 9757395
    [No Abstract]   [Full Text] [Related]  

  • 55. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.
    Corinaldesi R; Valentini M; Belaïche J; Colin R; Geldof H; Maier C
    Aliment Pharmacol Ther; 1995 Dec; 9(6):667-71. PubMed ID: 8824655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug interactions. Proton pump inhibitors II].
    Zaigler M
    Internist (Berl); 1998 Sep; 39(9):978-9. PubMed ID: 9788120
    [No Abstract]   [Full Text] [Related]  

  • 57. Pantoprazole-induced acute interstitial nephritis.
    Moore I; Sayer JA; Nayar A; Ahmed S; Tapson JS
    J Nephrol; 2004; 17(4):580-1. PubMed ID: 15372423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cross reactivity among proton pump inhibitors: does it exits?].
    Garmendia Zallo M; Sánchez Azkarate A; Kraemer Mbula R; Liarte Ruano I; Nuñez Hernandez A; Cid De Rivera C
    Allergol Immunopathol (Madr); 2004; 32(2):92-5. PubMed ID: 15087098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continuing development of acid pump inhibitors: site of action of pantoprazole.
    Shin JM; Besancon M; Prinz C; Simon A; Sachs G
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.